Corporate Sclerosis
- All
- News
-
US Rules In Mylan's Favour, Invalidates Teva Patents: Natco
Drug firm Natco Pharma said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating two of Israel-based Teva Pharmaceuticals' patents related to multiple sclerosis drug Copaxone 40 mg/mL.
-
Glenmark, Sanofi End Pact for New Multiple Sclerosis Therapy
Glenmark Pharmaceuticals' licensing deal with Sanofi for a new molecule - Vatelizumab - aimed at treating multiple sclerosis (MS) has ended with the French drug major deciding against pursuing it as the molecule did not meet the primary efficacy endpoint.
-
Natco's Partner Mylan Inc Files ANDA for Generic Copaxone
Drug firm Natco Pharma today said its marketing partner in America, Mylan Inc has filed an ANDA for generic Copaxone used in treatment of multiple sclerosis and expects 180 days of marketing exclusivity.
-
US Patents rejects Teva's plea on Copaxone; Natco shares up
The United States Patent and Trademark Office (the "PTO") issued a final office action rejecting Teva's application seeking a reissue of US Patent No. 5,800,808 (the "'808 Patent"), which was found to be invalid by the Court of Appeals for the Federal Circuit in July 2013
-
Glenmark gets US regulator nod for sclerosis treatment drug
Riluzole is indicated for the treatment of amyotrophic lateral sclerosis. As per the IMS Health sales data for the 12 month period ended March 2013, Riluzole had garnered sales of $64 million in the US market.
-
How giant Google aims to stop brain drain
When a product manager at Google told his bosses this year that he was quitting to take a job at Facebook, they offered him a large raise. When he said it was not about the money, they told him he could have a promotion, work in a different area or even start his own company inside Google. He turned down all the inducements and joined Google's newe...
-
US Rules In Mylan's Favour, Invalidates Teva Patents: Natco
Drug firm Natco Pharma said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating two of Israel-based Teva Pharmaceuticals' patents related to multiple sclerosis drug Copaxone 40 mg/mL.
-
Glenmark, Sanofi End Pact for New Multiple Sclerosis Therapy
Glenmark Pharmaceuticals' licensing deal with Sanofi for a new molecule - Vatelizumab - aimed at treating multiple sclerosis (MS) has ended with the French drug major deciding against pursuing it as the molecule did not meet the primary efficacy endpoint.
-
Natco's Partner Mylan Inc Files ANDA for Generic Copaxone
Drug firm Natco Pharma today said its marketing partner in America, Mylan Inc has filed an ANDA for generic Copaxone used in treatment of multiple sclerosis and expects 180 days of marketing exclusivity.
-
US Patents rejects Teva's plea on Copaxone; Natco shares up
The United States Patent and Trademark Office (the "PTO") issued a final office action rejecting Teva's application seeking a reissue of US Patent No. 5,800,808 (the "'808 Patent"), which was found to be invalid by the Court of Appeals for the Federal Circuit in July 2013
-
Glenmark gets US regulator nod for sclerosis treatment drug
Riluzole is indicated for the treatment of amyotrophic lateral sclerosis. As per the IMS Health sales data for the 12 month period ended March 2013, Riluzole had garnered sales of $64 million in the US market.
-
How giant Google aims to stop brain drain
When a product manager at Google told his bosses this year that he was quitting to take a job at Facebook, they offered him a large raise. When he said it was not about the money, they told him he could have a promotion, work in a different area or even start his own company inside Google. He turned down all the inducements and joined Google's newe...
